(S)-(3-(9-ethyl-8-(2-methylpyrimidin-5-yl)-9H-purin-6-ylamino)pyrrolidin-1-yl)(oxazol-4-yl)methanone

ID: ALA4869910

PubChem CID: 90168951

Max Phase: Preclinical

Molecular Formula: C20H21N9O2

Molecular Weight: 419.45

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  CCn1c(-c2cnc(C)nc2)nc2c(N[C@H]3CCN(C(=O)c4cocn4)C3)ncnc21

Standard InChI:  InChI=1S/C20H21N9O2/c1-3-29-18(13-6-21-12(2)22-7-13)27-16-17(23-10-24-19(16)29)26-14-4-5-28(8-14)20(30)15-9-31-11-25-15/h6-7,9-11,14H,3-5,8H2,1-2H3,(H,23,24,26)/t14-/m0/s1

Standard InChI Key:  PIGUHLRPVFFTQD-AWEZNQCLSA-N

Molfile:  

 
     RDKit          2D

 31 35  0  0  0  0  0  0  0  0999 V2000
   14.1192  -13.3640    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.1151  -12.5468    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.8208  -12.1346    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.5651  -12.4609    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.1089  -11.8508    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.6967  -11.1451    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.8983  -11.3192    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.0252  -10.3969    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   15.5415   -9.7382    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   14.1254  -14.9966    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   14.8334  -14.5800    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   14.8261  -13.7649    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   13.4151  -14.5907    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   13.4094  -13.7765    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.6333  -13.5301    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.1592  -14.1922    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.6424  -14.8476    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   11.3420  -14.1984    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.3952  -15.6266    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.9307  -13.4920    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1556  -13.4483    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.7103  -14.2091    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1286  -14.9160    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   10.9436  -14.9067    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8931  -14.2163    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.5971  -15.8020    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   16.8375  -10.3073    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   17.3835  -10.9116    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   18.1283  -10.5753    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   18.0387   -9.7630    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   17.2385   -9.5974    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  3  2  1  6
  3  4  1  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  7  3  1  0
  6  8  1  0
  8  9  2  0
  1 14  2  0
 13 10  2  0
 10 11  1  0
 11 12  2  0
 12  1  1  0
 13 14  1  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 13  1  0
 16 18  1  0
 17 19  1  0
 18 20  2  0
 20 21  1  0
 21 22  2  0
 22 23  1  0
 23 24  2  0
 24 18  1  0
 22 25  1  0
 19 26  1  0
  8 27  1  0
 27 28  1  0
 28 29  2  0
 29 30  1  0
 30 31  1  0
 31 27  2  0
M  END

Alternative Forms

1. Parent:

   

   ALA4869910

   [(3S)-3-[[9-ethyl-8-(2-methylpyrimidin-5-yl)purin-6-yl]amino]pyrrolidin-1-yl]-(1,3-oxazol-4-yl)methanone

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 419.45

Molecular Weight (Monoisotopic): 419.1818

AlogP: 1.93

#Rotatable Bonds: 5

Polar Surface Area: 127.75

Molecular Species: NEUTRAL

HBA: 10

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 11

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 1

CX Acidic pKa: ┄

CX Basic pKa: 4.39

CX LogP: 0.40

CX LogD: 0.40

Aromatic Rings: 4

Heavy Atoms: 31

QED Weighted: 0.52

Np Likeness Score: -1.35

References

1. Methot JL, Zhou H, McGowan MA, Anthony NJ, Christopher M, Garcia Y, Achab A, Lipford K, Trotter BW, Altman MD, Fradera X, Lesburg CA, Li C, Alves S, Chappell CP, Jain R, Mangado R, Pinheiro E, Williams SMG, Goldenblatt P, Hill A, Shaffer L, Chen D, Tong V, McLeod RL, Lee HH, Yu H, Shah S, Katz JD..  (2021)  Projected Dose Optimization of Amino- and Hydroxypyrrolidine Purine PI3Kδ Immunomodulators.,  64  (8.0): [PMID:33797901] [10.1021/acs.jmedchem.1c00237]

Source

Source(1):

• Scientific Literature